



Review

Community-Acquired Pneumonia Among Smokers[☆]Jordi Almirall,^{a,*} José Blanquer,^b Salvador Bello^c^a Servicio de Cuidados Intensivos, Hospital de Mataró, Universitat Autònoma de Barcelona, CIBERES, Barcelona, Spain^b Cuidados Intensivos Respiratorios, Hospital Clínico Universitario, INCLIVA, Valencia, Spain^c Servicio de Neumología, Hospital Universitario Miguel Servet, CIBERES, Zaragoza, Spain

ARTICLE INFO

Article history:

Received 20 September 2013

Accepted 19 November 2013

Available online 10 May 2014

Keywords:

Smoking

Community-acquired pneumonia

Risk factors

Prevention

ABSTRACT

Recent studies have left absolutely no doubt that tobacco increases susceptibility to bacterial lung infection, even in passive smokers. This relationship also shows a dose-response effect, since the risk reduces spectacularly 10 years after giving up smoking, returning to the level of non-smokers.

Streptococcus pneumoniae is the causative microorganism responsible for community-acquired pneumonia (CAP) most frequently associated with smoking, particularly in invasive pneumococcal disease and septic shock.

It is not clear how it acts on the progress of pneumonia, but there is evidence to suggest that the prognosis for pneumococcal pneumonia is worse.

In CAP caused by *Legionella pneumophila*, it has also been observed that smoking is the most important risk factor, with the risk rising 121% for each pack of cigarettes smoked a day.

Tobacco use may also favor diseases that are also known risk factors for CAP, such as periodontal disease and upper respiratory viral infections.

By way of prevention, while giving up smoking should always be proposed, the use of the pneumococcal vaccine is also recommended, regardless of the presence of other comorbidities.

© 2013 SEPAR. Published by Elsevier España, S.L. All rights reserved.

Neumonía adquirida en la comunidad en fumadores

RESUMEN

En estudios recientes ha quedado perfectamente establecido que el tabaco incrementa la susceptibilidad a la infección bacteriana pulmonar, incluso en fumadores pasivos. Este efecto muestra también dosis-respuesta, ya que disminuye espectacularmente el riesgo 10 años después de abandonar el hábito tabáquico, situándose a niveles de no fumadores.

Streptococcus pneumoniae es el microorganismo causante de neumonía adquirida en la comunidad (NAC) que más se ha relacionado con el tabaquismo, especialmente en situaciones de enfermedad neumocócica invasiva y shock séptico.

Su influencia sobre la evolución de la neumonía no parece clara, aunque existen evidencias que sugieren un peor pronóstico de la neumonía neumocócica.

En NAC causadas por *Legionella pneumophila* también se ha observado que el hábito tabáquico es el factor de riesgo más remarcable, ya que puede suponer un aumento del riesgo del 121% por cada paquete diario de cigarrillos consumidos.

Por otro lado, el consumo de tabaco puede también favorecer la presencia de enfermedades que a su vez son factores de riesgo conocidos de NAC, como enfermedades periodontales e infecciones víricas de la vía aérea superior.

Como medida preventiva, si bien cabe proponer el abandono del tabaco, también es recomendable la vacuna neumocócica, independientemente de la presencia de comorbilidad.

© 2013 SEPAR. Publicado por Elsevier España, S.L. Todos los derechos reservados.

Palabras clave:

Tabaquismo

Neumonía adquirida en la comunidad

Factores de riesgo

Prevención

[☆] Please cite this article as: Almirall J, Blanquer J, Bello S. Neumonía adquirida en la comunidad en fumadores. Arch Bronconeumol. 2014;50:250–254.

* Corresponding author.

E-mail address: jalmirall@csdm.cat (J. Almirall).

The adverse effects of tobacco smoking make it one of the most important risk factors for major chronic cardiovascular and respiratory diseases. In some of these, tobacco use may worsen prognosis, while for others there is a clear causal relationship.

Chronic obstructive pulmonary disease (COPD) and lung cancer are among the most common smoking-related diseases, but there is also evidence linking smoking with diseases such as asthma, interstitial and allergic diseases, and pulmonary infections.¹ Indeed, the airway is constantly exposed to microorganisms, but the healthy lung has sufficient defense mechanisms to prevent microbial invasion (effective mucociliary clearance, epithelial barrier integrity, alveolar macrophages that recognize and phagocytose invading microorganisms). Any failure of these mechanisms may result in microorganisms spreading to the bronchial tree, triggering community-acquired pneumonia (CAP), which remains a major cause of morbidity and mortality in developed countries. In the general adult population, the annual incidence of CAP varies between 1.6 and 13.4 cases per 1000 inhabitants, with a hospitalization rate of between 22 and 51% and a mortality rate of 3%–24%^{2–4} that has not changed in recent years, despite the preventive measures undertaken.⁵

Smoking and Pneumonia

The most important risk factor for CAP is age. So much so, that the incidence triples or quadruples when age is >65 years.² The reason is unclear, but several factors may be involved, related to immune senescence due to weakness (innate and adaptive) of the immune system, increased asymptomatic aspirations in this age group,⁶ or the convergence of other risk factors (RF) that do not acquire statistical significance in younger people, but that take center stage in older age groups, possibly due to an additive effect. One of these factors may be tobacco smoking, the main RF for COPD, which in turn is one of the main RFs for CAP. Thus, it is often difficult to determine the specific weight of smoking in the development of CAP, especially considering that smoking is associated with lower socioeconomic status, poor diet, increased alcohol consumption, and reduced physical activity, that are also RFs for respiratory infection.⁷ Nevertheless, enough studies using statistical analysis with logistic regression models are now available to allow the differentiation of any confounding factors, showing that tobacco smoking in itself increases the risk of pneumonia. In this regard, a population-based study^{2,3} was published that demonstrated an increased risk of CAP in smokers that was also directly related to the duration of tobacco consumption and the number of cigarettes consumed. Concurrently, it has been shown that this risk disappears when smokers quit. In fact, after 5 years, the risk decreases by 50%.³ Moreover, if we consider that one of the criteria for causality between two factors is dose-response, the increase in risk associated with an increase in intensity of consumption and the overall amount of tobacco consumed further reinforces the notion that tobacco smoking is a direct causal agent of CAP. On the other hand, we know that tobacco smoking causes morphological changes in the epithelium of the bronchial mucosa, with loss of cilia, mucous gland hypertrophy and increased goblet cells that may favor the presence and spread of microbes in the bronchial tree. An inflammatory reaction is produced in the airway causing macrophage and neutrophil activation that releases proteases. Oxidative stress and cytokine release are triggered, leading to both innate and adaptive immune response.^{8–14} This may in turn make the bronchial mucosa epithelium more sensitive to the inflammatory aggression of the infection itself.^{15–17} Moreover, it is now known that tobacco smoking inhibits some of the key functions of the innate and adaptive response, including the response of two Toll-like receptors (TLR2),¹⁸ nuclear factor kappaB (NF-κB),⁸

CD4-lymphocyte proliferation (LTCD4),^{12,19} maturation of dendritic cells,¹⁰ and opsonization and phagocytosis capacities.²⁰ Thus, tobacco smoking can alter immunity against infection, affecting the modulation of intra- and intercellular signaling of epithelium and immune cells, and suppressing the activation of important elements of the innate and adaptive immune response.^{17,21} The fact that tobacco smoking increases susceptibility to bacterial infection is well established.^{22,23}

Passive Smoking and Pneumonia

Passive smoking is considered a major epidemiological problem. In 2004, an international study including 192 countries found that 40% of children, 33% of male non-smokers and 35% of female non-smokers, were passive smokers.²⁴ There were wide geographical variations that could be explained by the different stages of the tobacco smoking epidemic in the country surveyed, because passive smoking is directly related to active smoking rates. In the year 2005, prevalence data in Spain estimated that about 50% of adults were exposed to second-hand smoke.²⁵ Later, as in most developed countries, legislation was introduced to regulate tobacco smoking in public places. This has reduced exposure to tobacco smoke by approximately 20%–25%, due to falling consumption in public places and in the workplace, but not at home. Accordingly, in recent years there has been growing interest in understanding the effect of passive tobacco smoking and some studies suggest that it could also involve a higher risk of respiratory infections in both the children of smoking parents,^{26,27} and in adults.^{28,29} Allowing smoking in the home has also been shown to be an important predictor of health loss in elderly people with CAP.³⁰ In fact, lesions in the respiratory epithelium, connective tissue and vascular endothelium of the lung caused by tobacco smoke can occur even at low smoke concentrations,³¹ supporting the notion that exposure to tobacco smoke could be an important risk factor for CAP development in passive smokers.

Two separate case-controlled,³² population-based studies have also demonstrated that passive smoking is a risk factor for developing pneumococcal bacteremia in immunocompetent adults, resulting in an odds ratio (OR) of 2.6 and attributable risk (AR) of 31% in subjects aged <65 years,^{28,33} and OR 2.2 and AR 13% in those over 65 years of age.^{28,32}

Smoking and Pneumococcal Pneumonia

The most common causative organism of CAP, regardless of care level and severity, is *Streptococcus pneumoniae*. This has also been shown to be the agent most frequently linked to smoking, especially in patients with COPD. An *in vitro* study has shown increased adherence of *S. pneumoniae* to the epithelial cells in the oral cavity of smokers,³⁴ persisting for up to three years after smoking cessation. This may produce greater oropharyngeal colonization and lead to greater chance of developing CAP.

Smoking has also been related with invasive pneumococcal disease (IPD), which in approximately 80% of cases is due to pneumonia.³⁵ This association was reported in a study by Pastor et al. in 1995, with an OR of 2.6 in smokers between 24 and 64 years of age and OR of 2.2 in smokers older than 65 years. Attributable risk (AR) was 31% in the first group and 13% in the second group.³ Another population-based, case-controlled study²⁸ also highlighted that smoking is the largest independent RF for IPD in immunocompetent adults, with an OR=4.1 in current smokers (AR 51%). Furthermore, there is a dose-response effect, and smoking cessation dramatically reduces the risk after 10 years, when it becomes the same as that of nonsmokers.

The special relationship of active smoking with pneumococcus has been demonstrated by some studies that have shown tobacco-induced changes in the clearance and phagocytosis of *S. pneumoniae* in the lungs,³⁶ and inhibition of the anti-pneumococcal activity of some innate immunity antimicrobial peptides.^{37,38} Thus, tobacco smoking impairs immunity to infection, especially against some microorganisms, including *S. pneumoniae*, and it seems well established that active smoking increases the risk of pneumonia.

However, the information as to whether active smokers have a worse CAP prognosis is not so clear. Three longitudinal studies^{39–41} involving large patient cohorts found higher mortality in smokers with pneumonia, while two metaanalyses^{42,43} found that tobacco smoking did not affect prognosis. Two large retrospective series that studied CAP mortality in relation to tobacco smoking have shown contradictory results.^{44,45} Finally, a recent study showed that tobacco smoking was an independent risk factor for septic shock in pneumococcal pneumonia,⁴⁶ and another epidemiological study concluded that smoking was an independent determinant of mortality in bacteremic CAP caused by *S. pneumoniae*.⁴⁷ Considering all these data, we can conclude that there is evidence to suggest worse prognosis of pneumococcal pneumonia in active smokers, while the picture is not so clear if we consider overall CAP, independent of the etiology.

Smoking and *Legionella pneumophila* Pneumonia

Less frequent, but not less important, is CAP due to *Legionella pneumophila*. Its incidence varies according to published series: some report sporadic cases while in others it is the second or third most common etiologic agent. This depends on epidemiological factors, the completeness of the diagnostic method used, and the severity of CAP, among other factors. In population-based studies, *L. pneumophila* represents 1%–3% of diagnosed microorganisms.⁴⁸ This type of CAP usually affects young individuals, often without underlying disease.⁴⁹ Smoking is the most important risk factor in these subjects, as the risk may be increased by 121% for each pack of cigarettes consumed daily, with OR of 3.48,⁵⁰ and as much as 7.49 if analyzed in people without comorbidities. This increased risk is attributed to the difficulty in eradicating the microorganism from the bronchial tree, due to the deterioration of the respiratory mucosa and impaired cilia caused by tobacco smoking that, depending on the individual's immune status, facilitates entry into and subsequent invasion of the alveolar macrophages.

Smoking and Other Risk Factors of Pneumonia Acquired in the Community

Tobacco smoking may also favor the presence of diseases which are in turn known risk factors of CAP, including:

- Periodontal diseases directly related to the development of CAP.⁵¹ Poorer oral hygiene has been shown to potentially lead to increased respiratory infection.^{52,53} Additionally, smokers show higher subgingival bacterial colonization than non-smokers, which is directly related to the number of cigarettes smoked by day. Accordingly, smokers of fewer than 10 cigarettes/day present periodontitis between 2.5 and 6 times more often than non-smokers (OR 2.79), while OR is 5.88 for those smoking >30 cigarettes/day; OR decreases dramatically if the habit is quit and can reach OR 1.15 after 11 years.⁵⁴
- Viral upper respiratory tract infections. Upper respiratory tract infections (URTI) are a risk factor of CAP, independent of other related factors,^{2,7} and smoking independently influences the

presence of prior viral infection. Blake et al.⁵⁵ observed in a cohort of soldiers diagnosed with URTI that 22.7% were smokers, vs 16% non-smokers (RR: 1.5). Increased susceptibility to experimental viral infection has also been observed in smokers.⁵⁶

Prevention

At present there is enough scientific evidence to show that active tobacco smoking is an important risk factor for CAP^{26,28,29,33}; it has a direct and independent effect on the risk of CAP, but it may also act indirectly causing chronic bronchitis or COPD which, in turn, are well recognized risk factors for CAP.^{7,33} Therefore, one of the main ways of preventing CAP is to intervene in the smoking habit, advising its cessation, which may reduce the risk of CAP by 50% after five years.³ Furthermore, a reduction of 14% in IPD has been observed every year²⁸ and, after 10 years, the risk of IPD can reach the same level as that of non-smokers.

On the other hand, pneumococcal vaccine is concomitantly recommended. In fact, the American scientific societies propose tobacco cessation combined with pneumococcal vaccine in patients hospitalized for CAP,⁵⁷ and further recommend the pneumococcal vaccine for active smokers in the population aged between 19 and 64 years, regardless of the presence of comorbidities.⁵⁸ This recommendation is even more relevant for active smokers, in whom lower rates of influenza and pneumococcal immunization have been observed compared to former smokers and non-smokers.⁵⁹

At present, two types of vaccine are available: the 23-valent polysaccharide vaccine and 13-valent conjugated vaccine. The former has been used in Spain since 1999, and protective effect has been found in studies not designed to assess its effectiveness,^{7,60} while clinical trials to test its efficacy against IPD do not establish such an effect, and effectiveness on CAP in general cannot be estimated.⁶¹ Therefore, pneumococcal immunization with the 13-valent conjugate vaccine, authorized for adults in Europe since October 2011 and in Spain since July 2012, has been recently recommended.⁶² The main advantage over the former is that, being conjugated, it is capable of inducing a T-dependent immune response that provides a better immune response and generates immune memory.⁶³ Additionally, it has been described to generate IgA responses in mucosa, reducing nasopharyngeal colonization by serotypes represented in the vaccine, thus breaking the infectious cycle and producing group immunity.⁶⁴ Furthermore, the serotype coverage of the 13-valent conjugate vaccine reaches up to 82% of CAP-producing agents in healthy adults.⁶⁵ Therefore, it seems clear that the smoking population should be considered as a target for pneumococcal vaccination strategies.⁶⁶

Conflicts of Interest

The authors declare no conflicts of interest.

References

1. Aubry MC, Wright JL, Myers JL. The pathology of smoking-related lung diseases. *Clin Chest Med*. 2000;21:11–35.
2. Almirall J, Bolibar I, Balanzó X, González CA. Risk factors for community-acquired pneumonia in adults: a population-based case control study. *Eur Respir J*. 1999;13:349–55.
3. Almirall J, Gonzalez CA, Balanzó X, Bolibar I. Proportion of community-acquired pneumonia cases attributable to tobacco smoking. *Chest*. 1999;116:375–9.
4. Piatti G, Gazzola T, Allegra L. Bacterial adherence in smokers and non-smokers. *Pharmacol Res*. 1997;36:481–4.

5. Gil-Prieto R, García-García L, Álvaro-Meca A, Méndez C, García A, Gil de Miguel A. The burden of hospitalisations for community-acquired pneumonia (CAP) and pneumococcal pneumonia in adults in Spain (2003–2007). *Vaccine*. 2011;29:412–6.
6. Almirall J, Rofes L, Serra-Prat M, Icart R, Palomera E, Arreola V, et al. Oropharyngeal dysphagia is a risk factor for community-acquired pneumonia in the elderly. *Eur Respir J*. 2013;41:923–8.
7. Almirall J, Bolibar I, Serra-Prat M, Roig J, Hospital I, Carandell E, et al. New evidence of risk factors for community-acquired pneumonia: a population-based study. *Eur Respir J*. 2008;31:1274–84.
8. Vernooij JH, Bracke KR, Drummen NE, Pauwels NS, Zabeau L, van Suylen RJ, et al. Leptin modulates innate and adaptive immune cell recruitment after cigarette smoke exposure in mice. *J Immunol*. 2010;184:7169–77.
9. Manzel LJ, Shi L, O'Shaughnessy PT, Thorne PS, Look DC. Inhibition by cigarette smoke of nuclear factor- κ B-dependent response to bacteria in the airway. *Am J Respir Cell Mol Biol*. 2011;44:155–65.
10. Feng Y, Kong Y, Barnes P, Huang FF, Klucar P, Wang X, et al. Exposure to cigarette smoke inhibits the pulmonary T-cell response to influenza virus and *Mycobacterium tuberculosis*. *Infect Immun*. 2011;79:229–37.
11. Mortaz E, Kraneveld AD, Smit JJ, Kool M, Lambrecht BN, Kunkel SL, et al. Effect of cigarette smoke extract on dendritic cells and their impact on T-cell proliferation. *PLoS ONE*. 2009;4:e4946.
12. Nizri E, Irony-Tur-Sinai M, Lory O, Orr-Urtreger A, Lavi E, Brenner T, et al. Activation of the cholinergic anti-inflammatory system by nicotine attenuates neuroinflammation via suppression of Th1 and Th17 responses. *J Immunol*. 2009;183:6681–8.
13. Hodge S, Hodge G, Ahern J. Smoking alters alveolar macrophage recognition and phagocytic ability. *Am J Respir Cell Mol Biol*. 2007;37:748–55.
14. Mehta H, Nazzari K, Sadikot RT. Cigarette smoking and innate immunity. *Inflamm Res*. 2008;57:497–503.
15. Chung KF, Adcock IM. Oxidative stress and redox regulation of lung inflammation in COPD. *Eur Respir J*. 2006;28:219–42.
16. Barnes PJ. Neutrophils find smoke attractive. *Science*. 2010;330:40–1.
17. Arnson Y, Shoenfeld Y, Amital H. Effects of tobacco smoke on immunity, inflammation and autoimmunity. *J Autoimmun*. 2010;34:258–65.
18. Droemann D, Goldmann T, Tiedje T, Zabel P, Dalhoff K, Schaaf B. Toll-like receptor 2 expression is decreased on alveolar macrophages in cigarette smokers and COPD patients. *Respir Res*. 2005;6:68.
19. Vassallo R, Tamada K, Lau JS, Kroening PR, Chen L. Cigarette smoke extract suppresses human dendritic cell function leading to preferential induction of Th-2 priming. *J Immunol*. 2005;175:2684–91.
20. Qvarfordt I, Riise GC, Andersson BA, Larsson S. IgG subclasses in smokers with chronic bronchitis and recurrent exacerbations. *Thorax*. 2001;56:445–9.
21. Modestou MA, Manzel LJ, El-Mahdy S, Look DC. Inhibition of IFN- γ -dependent antiviral airway epithelial defense by cigarette smoke. *Respir Res*. 2010;11:64.
22. Bagaitkar J, Demuth RDR, Scott DA. Tobacco use increases susceptibility to bacterial infection. *Tob Ind Dis*. 2008;4:12.
23. Huttunen R, Heikkinen T, Syrjänen J. Smoking and the outcome of infection. *J Intern Med*. 2011;269:258–69.
24. Oberg M, Jaakkola MS, Woodward A, Peruga A, Prüss-Ustün A. Worldwide burden of disease from exposure to second-hand smoke: a retrospective analysis of data from 192 countries. *Lancet*. 2011;377:139–46.
25. Jiménez-Ruiz CA, Miranda JA, Hurt RD, Pinedo AR, Reina SS, Valero SC. Study of the impact of laws regulating tobacco consumption on the prevalence of passive smoking in Spain. *Eur J Public Health*. 2008;18:622–5.
26. Vinogradova Y, Hippisley-Cox J, Coupland C. Identification of new risk factors for pneumonia: population-based case-control study. *Br J Gen Pract*. 2009;59:e882–7.
27. Jones LL, Hashim A, McKeever T, Cook DG, Britton J, Leonardi-Bee J. Parental and household smoking and the increased risk of bronchitis, bronchiolitis and other lower respiratory infections in infancy: systematic review and meta-analysis. *Respir Res*. 2011;12:5.
28. Nuorti JP, Butler JC, Farley MM, Harrison LH, Mc Geer A, Kolczak MS, et al. Active bacterial core surveillance team. Cigarette smoking and invasive pneumococcal disease. *N Engl J Med*. 2000;342:681–9.
29. Loeb M, Neupane B, Walter SD, Hanning R, Carusone SC, Lewis D, et al. Environmental risk factors for community-acquired pneumonia hospitalization in older adults. *J Am Geriatr Soc*. 2009;57:1036–40.
30. Fernandez E, Krueger P, Loeb M. Predictors of health decline in older adults with pneumonia: findings from the community-acquired pneumonia impact study. *BMC Geriatr*. 2010;10:1–7.
31. Strulovici-Barel Y, Omberg L, O'Mahony M, Gordon C, Hollmann C, Tilley AE, et al. Threshold of biologic responses of the small airway epithelium to low levels of tobacco smoke. *Am J Respir Crit Care Med*. 2010;182:1524–32.
32. Hoffman LH, Stratton DR, Stang PE, Hogue SL. Impact of smoking on respiratory illness-related outpatient visits among 50- to 75-year-old in the United States. *Clin Ther*. 2002;24:317–24.
33. Pastor P, Medley F, Murphy TV. Invasive pneumococcal disease in Dallas County, Texas: results from population-based surveillance in 1995. *Clin Infect Dis*. 1998;26:590–5.
34. Raman AS, Swinburne AJ, Fedullo AQJ. Pneumococcal adherence to the buccal epithelial cells of cigarette smokers. *Chest*. 1983;83:23–7.
35. Rueda AM, Serpa JA, Matloobi M, Mushtakq M, Musher DM. The spectrum of invasive pneumococcal disease at an adult tertiary care hospital in the early 21st century. *Medicine (Baltimore)*. 2012;89:331–6.
36. Phipps JC, Aronoff DM, Curtis JL, Goel D, O'Brien E, Mancuso P. Cigarette smoke exposure impairs pulmonary bacterial clearance and alveolar macrophage complement-mediated phagocytosis of *Streptococcus pneumoniae*. *Infect Immun*. 2010;78:1214–20.
37. Herr C, Beisswenger C, Hess C, Kandler K, Suttrop N, Welte T, et al., for the CAP-NETZ Study Group. Suppression of pulmonary innate host defence in smokers. *Thorax*. 2009;64:144–9.
38. Kilsgard O, Andersson P, Malmsten M, Nordin SL, Linge HM, Eliasson M, et al. Peptidylarginine deiminases present in the airways during tobacco smoking and inflammation can citrullinate the host defense peptide LL-37. Resulting in altered activities. *Am J Respir Cell Mol Biol*. 2012;46:240–8.
39. Gupta PC, Pednekar MS, Parkin DM, Sankaranarayanan R. Tobacco associated mortality in Mumbai (Bombay) India. Results of the Bombay Cohort Study. *Int J Epidemiol*. 2005;34:1395–402.
40. Doll R, Peto R, Wheatley K, Gray R, Sutherland I. Mortality in relation to smoking: 40 years' observations on male British doctors. *BMJ*. 1994;309:901–11.
41. Inoue Y, Koizumi A, Wada Y, Iso H, Watanabe Y, Date C, et al. Risk and protective factors related to mortality from pneumonia among middle aged and elderly community residents: the JACC Study. *J Epidemiol*. 2007;17:194–202.
42. Katanoda K, Marugame T, Saika K, Satoh H, Tajima K, Suzuki T, et al. Population attributable fraction of mortality associated with tobacco smoking in Japan: a pooled analysis of three large-scale cohort studies. *J Epidemiol*. 2008;18:251–64.
43. Fine MJ, Smith MA, Carson CA, Mutha SS, Sankey SS, Weissfeld LA, et al. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. *JAMA*. 1996;275:134–41.
44. Jha P, Jacob B, Gajalakshmi V, Gupta PC, Dhingra N, Kumar R, et al. A nationally representative case-control study of smoking and death in India. *N Engl J Med*. 2008;358:1137–47.
45. Sitas F, Urban M, Bradshaw D, Kielkowski D, Bah S, Peto R. Tobacco attributable deaths in South Africa. *Tob Control*. 2004;13:396–9.
46. Garcia-Vidal C, Ardanuy C, Tubau F, Viasus D, Dorca J, Liñares J, et al. Pneumococcal pneumonia presenting with septic shock: host- and pathogen related factors and outcomes. *Thorax*. 2010;65:77–81.
47. Naucner P, Darenberg J, Morfeldt E, Örtqvist A, Normark BH. Contribution of host, bacterial factors and antibiotic treatment to mortality in adult patients with bacteraemic pneumococcal pneumonia. *Thorax*. 2013;68:571–9.
48. Roig J, Sabrià M, Pedro-Botet ML. *Legionell* spp.: community acquired and nosocomial infections. *Curr Opin Infect Dis*. 2003;16:145–51.
49. Sopena N, Sabrià M, Pedro-Botet ML, Padilla E, Dominguez J, Morera J, et al. Comparative study of the clinical presentation of Legionella pneumonia and other community-acquired pneumonias. *Chest*. 1998;113:1195–200.
50. Straus WL, Plouffe JF, File Jr TM, Lipman HB, Hackman BH, Salstrom SJ, et al., Ohio Legionnaires Disease Group. Risk factors for domestic acquisition of legionnaires disease. *Arch Intern Med*. 1996;156:1685–92.
51. Arbes Jr SJ, Agustsdottir H, Slade GD. Environmental tobacco smoke and periodontal disease in the United States. *Am J Public Health*. 2001;91:253–7.
52. Mojon P, Budtz-Jorgensen E, Michel JP, Limeback H. Oral health and history of respiratory tract infection in frail institutionalised elders. *Gerodontology*. 1997;14:9–16.
53. Terpenning MS, Taylor GW, Lopatin DE, Kerr CK, Dominguez BL, Loesche WJ. Aspiration pneumonia: dental and oral risk factors in an older veteran population. *J Am Geriatr Soc*. 2001;49:557–63.
54. Tomar SL, Asma S. Smoking-attributable periodontitis in the United States: findings from NHANES III: National Health and Nutrition Examination Survey. *J Periodontol*. 2000;71:743–51.
55. Blake GH, Abell TD, Stanley WG. Cigarette smoking and upper respiratory infection among recruits in Basic combat training. *Ann Intern Med*. 1988;109:198–202.
56. Cohen S, Tyrrell DA, Russell MA, Jarvis MJ, Smith AP. Smoking, alcohol consumption and susceptibility to the common cold. *Am J Respir Cell Mol Biol*. 1996;14:225–31.
57. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al., Infectious Diseases Society of America: American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. *Clin Infect Dis*. 2007;44 Suppl. 2:527–72.
58. Centers for Disease Control and Prevention. Recommended adult immunization schedule, United States, 2011 proposed revisions. Advisory Committee on Immunization Practices; 2010.
59. Pearson WS, Dube SR, Ford ES, Mokdah AH. Influenza and pneumococcal vaccination rates among smokers: data from the 2006 Behavioral Risk Factor Surveillance System. *Prev Med*. 2009;48:180–3.
60. Arcavi L, Benowitz NL. Cigarette smoking and infection. *Arch Intern Med*. 2004;164:2206–16.
61. Moberley SA, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. *Cochrane Database Syst Rev*. 2008;CD000422.
62. Torres A, Barberán J, Falguera M, Menéndez R, Molina J, Olaechea P, et al. Guía multidisciplinaria para la valoración pronóstica, diagnóstica y tratamiento de la neumonía adquirida en la comunidad. *Med Clin (Barc)*. 2013;140:223–42.

63. Lazarus R, Clutterbuck E, Ly-Mee Y, Bowman J, Bateman EA, Diggle L, et al. A randomized study comparing combined pneumococcal conjugate and polysaccharide vaccination schedules in adults. *Clin Infect Dis*. 2011;52:736–42.
64. Feikin DR, Klugman KP. Historical changes in pneumococcal serogroup distribution: implications for the era of pneumococcal conjugate vaccines. *Clin Infect Dis*. 2002;35:547–55.
65. Grau I, Ardanuy C, Calatayud L, Rolo D, Domenech A, Liñares J, et al. Invasive pneumococcal disease in healthy adults: increase of empyema associated with the clonal-type Sweden1-ST306. *PLoS ONE*. 2012;7:e42595.
66. Picazo JJ, González-Romo F, García Rojas A, Pérez-Trallero E, Gil Gregorio P, de la Cámara R, et al. Consenso sobre la vacunación anti-neumocócica en el adulto con patología de base. *Rev Esp Quimioter*. 2013;26:232–52.